
Opinion|Videos|April 22, 2026
What the introduction of bispecific antibodies has meant for the treatment of multiple myeloma
Author(s)C. Brooke Adams, Pharm.D., BCOP
Bispecific antibodies are highly efficacious and have a milder side effect profile than other late-line treatments for multiple myeloma, according to Adams.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026
2
CONNECT data support CGM use in non-insulin type 2 diabetes management | ADA 2026
3
American Cancer Society adds blood and stool tests to colorectal screening guideline
4
Pivotal trial is recruiting for monthly GLP-1 for weight loss | ADA 2026
5






























